ClinicalTrials.gg
TerminatedNCT06834399Updated Feb 19, 2025

TATE and KN046 in MCRC

A Phase 2 interventional study of KN046 (PD-L1/CTLA4 BsAb) and TATE:Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization in Colorectal Cancer with Hepatic Metastases, sponsored by Zhejiang Raygene Pharmaceuticals Co., Ltd. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Zhejiang Raygene Pharmaceuticals Co., Ltd · Phase 2, Interventional, and Treatment

Why this study was terminated
Business Operation Strategy Adjustment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Apr 2023, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 603 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Enrollment
624th of 891
42 · median 80
Started
2023
with 140 others
Phase 2
349 of 1,136
177 open now
Registered
868th of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 624th largest by enrollment of the 891 interventional ones that give a count, is one of 141 that started in 2023, is one of 349 in phase 2, and was the 868th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.

03

Conditions studied

  • Colorectal Cancer with Hepatic Metastases

Keywords

  • Colorectal Cancer
  • Liver Metastasis
  • Tirapazamine
  • KN046 (PD-L1/CTLA-4 Bispecific Antibody)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Liver MSS/pMMR-mCRC;
  • mCRC progressed on at least two lines of standard chemotherapy;
  • ;
  • 0-1;
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior organ transplantation;
  • Oxygen saturation less than 92% in room air;
  • Prior disorder;
  • Major GI bleeding in the last 2 months;
  • Prior treatment with , anti-PD-L1, or anti-CTLA-4 antibody therapy, or any other antibody or drug that specifically targets T-cell co-stimulation or immune checkpoint pathways.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    TATE and KN046

    On Day 1, patients will receive KN046 at a dose of 5 mg/kg. On Day 8 (+/-1), patients will receive TATE (Tirapazamine 35 mg). Each treatment cycle is 21 days. Patients will receive two cycles of treatment. After necrosis of liver tumors, whether to continue TATE treatment in the third cycle and beyond will be decided by the study physician based on the extent of tumor necrosis.

    Drug: KN046 (PD-L1/CTLA4 BsAb) · Procedure: TATE:Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization

Interventions

  • DrugKN046 (PD-L1/CTLA4 BsAb)

    KN046 is administered every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, study end, or other discontinuation criteria are met.

  • ProcedureTATE:Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization

    TATE treatment is given every 21 days. Patients receive two initial cycles. Whether to continue TATE treatment from the third cycle onward is decided by the investigator based on tumor necrosis. If a patient experiences intrahepatic tumor progression (recurrence or new tumors) during follow-up after the third cycle and still meets the treatment criteria, additional TATE treatment may be given.

06

What researchers measure

Primary outcomes

  1. ORR

    Objective Response Rate (assessed by mRECIST/RECIST)

    Time frame: 24 months

  2. OS

    Overall Survival

    Time frame: 24 months

Secondary outcomes

  1. DCR

    Disease control rate

    Time frame: 24 months

  2. PFS

    Progression-free survival

    Time frame: 24 months

  3. survival rates

    6-month, 1-year, and 2-year survival rates

    Time frame: 24 months

07

Study locations

1 site
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No — International meeting report or medical Journal publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Dec 2024, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 19, 2025
StartActual
Apr 27, 2023
Primary completionActual
Dec 17, 2024
CompletionActual
Jan 9, 2025
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06834399
Lead sponsor
Zhejiang Raygene Pharmaceuticals Co., Ltd
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Apr 27, 2023
Primary completion
Dec 17, 2024
Completion
Jan 9, 2025
Last update
Feb 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion